ArticleAnais brasileiros de dermatologia
Post-finasteride syndrome.
Article in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Sexual dysfunction associated with 5α-reductase inhibitors in the treatment of androgenetic alopecia: a systematic review.Frontiers in medicine · 2026Pooled it
- Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis.Asian journal of andrologyPooled it
- Risks Associated with 5α-Reductase Inhibitor Use: Analysis of Adverse Drug Reactions Reported to EudraVigilance.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Persistent Sexual and Psychological Symptoms After Finasteride Discontinuation: A Cross-Sectional Observational Study.Journal of clinical medicine · 2026Article
- 5α-Reductase Isoenzymes: From Neurosteroid Biosynthesis to Neuropsychiatric Outcomes.NeuroSci · 2026Review
- Progress in the Application of Exosomes in Androgenetic Alopecia: Focusing on Molecular Mechanisms.International journal of nanomedicine · 2026Review
- Recent Advances in the Role of Fibroblast Growth Factors in Hair Follicle Growth.Biomolecules · 2025Review
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports.Pharmaceuticals (Basel, Switzerland) · 2025Article
- The combination of water extracts ofNutrition research and practice · 2025Article
- The Pharmacokinetics of Topical Finasteride 0.25% Spray in Chinese Adult Male Volunteers with Androgenic Alopecia: A Phase I Study.Advances in therapy · 2025Article
- Article
- Using 5 alpha reductase inhibitors safely: What primary care physicians need to know.Journal of family medicine and primary care · 2024Review
- Enhancing Quality of Life and Sexual Functioning in Female Androgenetic Alopecia: Therapeutic Potential of Hair Follicle-Derived Stem Cells.Healthcare (Basel, Switzerland) · 2024Article
- 5-alpha reductase inhibitors use in prostatic disease and beyond.Translational andrology and urology · 2023Review
- Article
- Effectiveness of Platelet-Rich Plasma Therapy in Androgenic Alopecia-A Meta-Analysis.Journal of personalized medicine · 2022Article
- Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.Journal of cosmetic dermatology · 2021Review
- Pharmacological Management of Pattern Hair Loss.Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India · 2021Review
- Bibliometric evaluation of Anais Brasileiros de Dermatologia (2013-2022).Anais brasileiros de dermatologiaArticle
- Combination and Rotational Therapy in Androgenetic Alopecia.Journal of cutaneous and aesthetic surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Finasteride is a 5α-reductase enzyme inhibitor that has been approved for the treatment of male androgenic alopecia since 1997. Over time, it has been considered a safe and well-tolerated drug with rare and reversible side effects. Recently there have been reports of adverse drug-related reactions that persisted for at least three months after discontinuation of this drug, and the term post-finasteride syndrome arose. It includes persistent sexual, neuropsychiatric, and physical symptoms. Studies to date cannot refute or confirm this syndrome as a nosological entity. If it actually exists, it seems to occur in susceptible people, even if exposed to small doses and for short periods, and symptoms may persist for long periods. Based on currently available data, the use of 5α-reductase inhibitors in patients with a history of depression, sexual dysfunction, or infertility should be carefully and individually assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.